

A

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
ARC 2589 CIP1

Total Pages in this Submission

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application  
Washington, D.C. 20231


Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY**

and invented by:

Michel J.N. Cormier, Sara Lee Sendelbeck, Anna Muchnik and Iris Ka Man Leung

JC542 U.S. PTO  
09/190887



If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 08/969,217

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Enclosed are:

### Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 37 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☐ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☒ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
ARC 2589 CIP1

Total Pages in this Submission

## Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets \_\_\_\_\_
- b. ☒ Informal Number of Sheets 11
4. ☒ Oath or Declaration <sup>partially executed</sup>
- a. ☒ Newly ~~executed~~ <sup>executed</sup> (original or copy) ☐ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement/PTO-1449 ☒ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EM 534 009 135 US

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
ARC 2589 CIP1

Total Pages in this Submission

## Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☒ Additional Enclosures (please identify below):

Petition Under 37 CFR Sec. 1.47(a) - 2 pp  
Declaration Supporting Petition Under 37 CFR Sec. 1.47(a) - 4 pp  
Exhibits A, B & C


## Fee Calculation and Transmittal

### CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	20	- 20 =	0	x \$22.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$82.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$790.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$790.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.  
☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.

- ☒ Charge the amount of \$790.00 as filing fee.  
☐ Credit any overpayment.  
☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.  
☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

  
Signature

D. Byron Miller  
ALZA Corporation  
950 Page Mill Road  
Palo Alto, CA 94303-0802  
(650) 496-8150

Dated:

cc:

**1                    BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL****2                    ELECTROTRANSPORT DELIVERY****3                    Technical Field**

**4**  
**5**  
**6**                    The invention relates generally to drug formulations used in  
**7** transdermal electrotransport drug delivery. More particularly, the invention  
**8** relates to buffered drug formulations for transdermal electrotransport delivery  
**9** using buffers which minimally compete with the drug for carrying electric  
**10** current and which have greater stability and a longer shelf life.  
**11**

**12                  Background of the Invention**

**13**                  Transdermal (i.e., through the skin) delivery of therapeutic  
**14** agents affords a comfortable, convenient and noninvasive technique for  
**15** administering drugs. The method provides several advantages over  
**16** conventional modes of drug delivery. For example, variable rates of  
**17** absorption and (e.g., hepatic) metabolism encountered in oral treatment are  
**18** avoided, and other inherent inconveniences -- e.g., gastrointestinal irritation  
**19** and the like -- are eliminated. Transdermal delivery also allows a high degree  
**20** of control over blood concentrations of a particular drug and is an especially  
**21** attractive administration route for drugs with narrow therapeutic indexes, short  
**22** half-lives and potent activities.

**23**                  Transdermal delivery can be either passive or active. Many  
**24** drugs are not suitable for passive transdermal drug delivery because of their  
**25** size, ionic charge characteristics and hydrophilicity. One method of  
**26** overcoming this limitation is the use of low levels of electric current to actively  
**27** transport drugs into the body through skin. This technique is known as  
**28** "electrotransport" or "iontophoretic" drug delivery. The technique provides a  
**29** more controllable process than passive transdermal drug delivery since the  
**30** amplitude, timing and polarity of the applied electric current is easily regulated  
**31** using standard electrical components. In this regard, electrotransport drug

09190887 111299

1 flux can be from 50% to several orders of magnitude greater than passive  
2 transdermal flux of the same drug.

3 Electrotransport devices generally employ at least two  
4 electrodes. Both of these electrodes are positioned in intimate electrical  
5 contact with some portion of the skin of the body. One electrode, called the  
6 active or donor electrode, is the electrode from which the therapeutic agent is  
7 delivered into the body. The other electrode, called the counter or return  
8 electrode, serves to close the electrical circuit through the body. In  
9 conjunction with the patient's skin, the circuit is completed by connection of  
10 the electrodes to a source of electrical energy, e.g., a battery, and usually to  
11 circuitry capable of controlling the current applied by the device through the  
12 patient.

13 Depending upon the electrical charge of the species to be  
14 delivered transdermally, either the anode or cathode may be the active or  
15 donor electrode. Thus, if the ionic substance to be driven into the body is  
16 positively charged, the positive electrode (the anode) will be the active  
17 electrode and the negative electrode (the cathode) will serve as the counter  
18 electrode, completing the circuit. On the other hand, if the ionic substance to  
19 be delivered is negatively charged, the cathodic electrode will be the active  
20 electrode and the anodic electrode will be the counter electrode.  
21 Alternatively, both the anode and the cathode may be used to deliver drugs of  
22 appropriate charge into the body. In this case, both electrodes are  
23 considered to be active or donor electrodes. In other words, the anodic  
24 electrode can deliver positively charged agents into the body while the  
25 cathodic electrode can deliver negatively charged agents into the body.

26 Existing electrotransport devices additionally require a reservoir  
27 or source of the therapeutic agent that is to be delivered into the body. Such  
28 drug reservoirs are connected to the anode or the cathode of the  
29 electrotransport device to provide a fixed or renewable source of one or more  
30 desired species or agents. Examples of reservoirs and sources include a  
31 pouch as described in U.S. Patent No. 4,250,878 to Jacobsen; a pre-formed

09190837 "11093  
36371 2806T60

1 gel body as disclosed in U.S. Patent No. 4,383,529 to Webster; and a glass  
2 or plastic container holding a liquid solution of the drug, as disclosed in the  
3 figures of U.S. Patent No. 4,722,726 to Sanderson et al.

4 Of particular interest herein is the transdermal delivery of  
5 peptides, polypeptides, and proteins because of the problems encountered  
6 with more common drug administration routes such as oral delivery.  
7 Polypeptide and protein molecules are highly susceptible to degradation by  
8 proteolytic enzymes in the gastrointestinal tract and are subjected to an  
9 extensive hepatic metabolism when taken orally. Thus, these substances  
10 usually require parenteral administration to achieve therapeutic levels in the  
11 patient's blood. The most conventional parenteral administration techniques  
12 are hypodermic injections and intravenous administration. Polypeptides and  
13 proteins are, however, inherently short acting in their biological activity,  
14 requiring frequent injections, often several times a day, to maintain the  
15 therapeutically effective levels needed. Patients frequently find this treatment  
16 regimen to be inconvenient and painful. Such therapy also includes risk of,  
17 e.g., infection.

18 Much effort has been expended to find other routes (other than  
19 parenteral injections) for effective administration of pharmaceutical agents,  
20 including polypeptides and proteins. Administration routes with fewer side  
21 effects as well as better patient compliance have been of particular interest.  
22 Such alternative routes have generally included "shielded" oral administration  
23 wherein the polypeptide/protein is released from a capsule or other container  
24 after passing through the low pH environment of the stomach, delivery  
25 through the mucosal tissues, e.g., the mucosal tissues of the lung with  
26 inhalers or the nasal mucosal tissues with nasal sprays, and implantable  
27 pumps. Unfortunately, these alternative routes of polypeptide/protein delivery  
28 have met with only limited success.

29 A number of investigators have disclosed electrotransport  
30 delivery of polypeptides and proteins. An early study by R. Burnette et al. J.  
31 Pharm. Sci. (1986) 75:738, involved in vitro skin permeation of thyrotropin

1 releasing hormone, a small tripeptide molecule. The electrotransport flux was  
2 found to be higher than passive diffusional flux. Chien et al. J. Pharm. Sci.  
3 (1988) 78:376, in both in vitro and in vivo studies, showed that transdermal  
4 delivery of vasopressin and insulin via electrotransport was possible. See,  
5 also, Maulding et al., U.S. Statutory Invention Registration No. H1160, which  
6 discloses electrotransport delivery of calcitonin in minipigs.

7               However, transdermal delivery of polypeptide and protein drugs  
8 has also encountered technical difficulties. For example, skin irritation can  
9 occur due to water hydrolysis at the interface between the electrode and the  
10 drug solution or electrolyte salt solution. The products of such hydrolysis,  
11 hydronium ions at the anode and hydroxyl ions at the cathode, compete with  
12 drug ions of like charge for delivery into the skin, altering skin pH and causing  
13 irritation. U.S. Patent No. 5,533,971, to Phipps et al., describes this problem  
14 in more detail and reports the use of amino acid buffers, including histidine  
15 buffers, for adjusting the pH of electrotransport device reservoirs to levels  
16 which cause less irritation. Histidine as well as Asp, Glu and Lys have been  
17 used for buffering (U.S. Patent 5,624,415). Additionally, certain polypeptide  
18 and protein drugs, particularly those that are not native to the animal being  
19 treated, may cause skin reactions, e.g., sensitization or irritation. Many  
20 polypeptide and protein drugs are also unstable and degrade rapidly. In this  
21 regard, International Publication No. WO 93/12812, published 8 July 1993,  
22 describes the use of histidine buffers to chemically stabilize growth hormone  
23 formulations. Unfortunately, histidine is not a commercially viable buffer in  
24 many electrotransport drug formulations due to its instability in aqueous  
25 solution, thereby making the shelf-life of the drug formulation unacceptably  
26 short.

27               Controlling pH and assuring conductivity of electrotransport  
28 formulations is a dilemma that has not been solved to date. Control of pH in  
29 electrotransport systems is usually achieved by introduction of classic buffers  
30 such as TRIS, acetate or phosphate buffers in the formulation. This results in  
31 introduction of competing ions (i.e., ions having the same sign charge as the

SECRET 20060450

1 drug ions) into the drug formulation. In addition, in these formulations, donor  
2 reservoir pH drifting (i.e., during device operation) and reduced conductivity  
3 occurs during transport due to depletion of the charged species. This is of  
4 particular concern when the electrotransport delivery of therapeutically active  
5 polypeptide drugs is considered. Because these compounds are present at  
6 low concentration in the donor reservoir formulation, the detrimental effects  
7 caused by competing ions, i.e., decreasing conductivity of the formulation,  
8 decreasing transdermal drug flux, formulation pH drifting, and local skin  
9 irritation, are likely to be more severe. Recently, crosslinked ion exchange  
10 polymers have been used in an attempt to solve this deadlock. To date, their  
11 use has raised additional problems. In addition to regulatory concerns linked  
12 to the presence of small molecular weight degradants in these polymers, it is  
13 now evident that they do not provide adequate electrical conductivity and their  
14 usefulness in controlling pH is still subject to debate. What is still needed is a  
15 method which provides pH control and conductivity of the electrotransport  
16 drug formulation without introduction of competing ions and which is  
17 accomplished with the use of small molecular weight compounds that are  
18 easy to characterize.

19 Although histidine has been used to buffer protein formulations  
20 (WO 93/12812), the use of hisitidine to buffer electrotransport drug  
21 formulations is problematic due to the poor chemical stability of histidine in  
22 aqueous solutions. Water is by far the most preferred liquid solvent for  
23 electrotransport drug formulations due to its excellent biocompatability when  
24 in contact with skin. The aqueous stability of histidine is so poor that the  
25 formulations are not able to achieve the minimum stable shelf life required by  
26 drug regulatory agencies.

27 Thus, alternative methods for buffering aqueous electrotransport  
28 drug formulations, and in particular polypeptide drug or protein formulations,  
29 would be desirable.

## Disclosure of the Invention

The present invention provides a buffered aqueous formulation for transdermal electrotransport delivery exhibiting excellent stability characteristics. The reservoir formulation may be a donor reservoir formulation containing a drug or other therapeutic agent to be transdermally delivered. Alternatively, the reservoir formulation may be a counter reservoir formulation containing an electrolyte (e.g., saline). The formulation comprises an aqueous solution of the drug or electrolyte buffered with a dipeptide buffer. The dipeptide buffer comprises a polypeptidic chain of two to five amino acids, and has an isoelectric pH at which the dipeptide carries no net charge. The aqueous solution has a pH which is within about 1.0 pH unit of the isoelectric pH. Preferably, the dipeptide has at least two pKa's which are separated by no more than about 3.5 pH units. Most preferably, the isoelectric pH of the dipeptide is between about 3 and 10. The concentration of the dipeptide buffer in the solution is preferably at least about 10mM. The dipeptide buffer is preferably selected from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg, Hydroxylysine-His, His-Hydroxytylsine, Ornithine-His, His-Lys, His-Ornithine and Lys-His. A particularly preferred dipeptide buffer is Gly-His.

The present invention also provides a method of buffering an aqueous solution of a drug or an electrolyte used for transdermal electrotransport delivery. The method includes providing in the solution a pH buffering amount of a dipeptide comprising a polypeptidic chain of two to five amino acids, and having an isoelectric pH at which the dipeptide carries no net charge. The aqueous solution has a pH which is within about 1.0 pH unit

1 of the isoelectric pH. Preferably, the dipeptide has at least two pKa's which  
2 are separated by no more than about 3.5 pH units. Most preferably, the  
3 isoelectric pH of the dipeptide is between about 3 and 10. The concentration  
4 of the dipeptide buffer in the solution is preferably at least about 10mM. The  
5 dipeptide buffer is preferably selected from the group consisting of Asp-Asp,  
6 Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu,, Lys-  
7 Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-  
8 Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser,  
9 His-Thr, His-Trp, His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His,  
10 Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His,  
11 Hydroxyproline-His, Leu-His, Ala-His, Gly-His, Beta-Alanylhistidine, Pro-His,  
12 Carnosine, Anserine, Tyr-Arg, Hydroxylysine-His, His-Hydroxytyrosine,  
13 Ornithine-His, His-Lys, His-Ornithine and Lys-His. A particularly preferred  
14 dipeptide buffer is Gly-His.

#### 15 16 **Brief Description of the Drawings**

17 Figure 1 is a graph showing ionic charge versus pH for the  
18 dipeptide buffer Gly-His.

19 Figure 2 is a graph showing charged ion species distribution  
20 versus pH for the dipeptide buffer Gly-His.

21 Figure 3 is a graph showing ionic charge versus pH for two prior  
22 art buffers.

23 Figure 4 is a graph showing charged ion species distribution  
24 versus pH for phosphoric acid, a prior art buffer.

25 Figure 5 is a graph of charged ion species distribution versus pH  
26 for 3-[N-morpholino]propanesulphonic acid (MOPS), a prior art buffer.

27 Figure 6 is a graph of charged ion species distribution versus pH  
28 for the dipeptide buffer Glu-His.

29 Figure 7 is a graph of charged ion species distribution versus pH  
30 for the dipeptide buffer His-Glu.

Figure 8 is an exploded view of a representative electrotransport drug delivery device which can be used with the present invention.

Figure 9 is a graph of human growth hormone degradation versus time using a Gly-His dipeptide buffer.

Figure 10 is a graph of human growth hormone degradation versus time using His, a non-dipeptide buffer.

Figure 11 is a graph of transdermal flux of a model decapeptide at varying Gly-His concentrations.

### **Modes for carrying out the Invention**

The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, electrochemistry and biochemistry within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T.E. Creighton, *Proteins: Structures and Molecular Properties* (W.H. Freeman and Company, 1993); A.L. Lehninger, *Biochemistry* (Worth Publishers, Inc., 1975); J.S. Newman, *Electrochemical Systems* (Prentice Hall, 1973); and A.J. Bard and L.R. Faulkner, *Electrochemical Methods, Fundamentals and Applications* (John Wiley & Sons, 1980).

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a polypeptide" includes a mixture of two or more polypeptides, and the like.

The following amino acid abbreviations are used throughout the text:

Alanine: Ala (A)	Arginine: Arg (R)
Asparagine: Asn (N)	Aspartic acid: Asp (D)
Cysteine: Cys (C)	Glutamine: Gln (Q)
Glutamic acid: Glu (E)	Glycine: Gly (G)
Histidine: His (H)	Isoleucine: Ile (I)

1	Leucine: Leu (L)	Lysine: Lys (K)
2	Methionine: Met (M)	Phenylalanine: Phe (F)
3	Proline: Pro (P)	Serine: Ser (S)
4	Threonine: Thr (T)	Tryptophan: Trp (W)
5	Tyrosine: Tyr (Y)	Valine: Val (V)

## 6

### 7 I. Definitions

8 In describing the present invention, the following terms will be  
9 employed, and are intended to be defined as indicated below.

10 The term "dipeptide" denotes any polypeptidic chain of 2 to 5  
11 amino acid residues. The term encompasses dipeptides, tripeptides,  
12 tetrapeptides, and pentapeptides, and particularly includes dipeptides and  
13 tripeptides which contain His, such as but not limited to, His-Gly, Gly-His, Ala-  
14 His, His-Ser and His-Ala.

15 The term "drug" and "therapeutic agent" are used  
16 interchangeably and are intended to have their broadest interpretation as any  
17 therapeutically active substance which is delivered to a living organism to  
18 produce a desired, usually beneficial, effect. In general, this includes  
19 therapeutic agents in all of the major therapeutic areas including, but not  
20 limited to, anti-infectives such as antibiotics and antiviral agents, analgesics  
21 including fentanyl, sufentanil, buprenorphine and analgesic combinations,  
22 anesthetics, anorexics, antiarthritics, antiasthmatic agents such as  
23 terbutaline, anticonvulsants, antidepressants, antidiabetic agents,  
24 antidiarrheals, antihistamines, anti-inflammatory agents, antimigraine  
25 preparations, antimotion sickness preparations such as scopolamine and  
26 ondansetron, antinauseants, antineoplastics, antiparkinsonism drugs,  
27 antipruritics, antipsychotics, antipyretics, antispasmodics, including  
28 gastrointestinal and urinary, anticholinergics, antiulceratives such as  
29 ranitidine, sympathomimetics, xanthine derivatives, cardiovascular  
30 preparations including calcium channel blockers such as nifedipene,  
31 beta-blockers, beta-agonists such as dobutamine and ritodrine,

1 antiarrhythmics, antihypertensives such as atenolol, ACE inhibitors such as  
2 enalapril, benzodiazepine antagonists such as flumazenil, diuretics,  
3 vasodilators, including general, coronary, peripheral and cerebral, central  
4 nervous system stimulants, cough and cold preparations, decongestants,  
5 diagnostics, hormones such as parathyroid hormone, hypnotics,  
6 immunosuppressives, muscle relaxants, parasympatholytics,  
7 parasympathomimetics, prostaglandins, proteins, peptides,  
8 psychostimulants, sedatives and tranquilizers.

9           The invention is also useful in the controlled delivery of  
10 polypeptide and protein drugs and other macromolecular drugs. These  
11 macromolecular substances typically have a molecular weight of at least  
12 about 300 daltons, and more typically a molecular weight in the range of  
13 about 300 to 40,000 daltons. Specific examples of peptides, and proteins  
14 and macromolecules in this size range include, without limitation, LHRH,  
15 LHRH analogs such as buserelin, gonadorelin, napharelin and leuprolide,  
16 GHRH, GHRF, insulin, insulotropin, heparin, calcitonin, octreotide, endorphin,  
17 TRH, NT-36 (chemical name: N=[[(s)-4-oxo-2-azetidiny]carbonyl]-L-histidyl-  
18 L-prolinamide), liprecin, pituitary hormones (e.g., HGH, HMG, HCG,  
19 desmopressin acetate, etc.), follicle luteoids,  $\alpha$ ANF, growth factors such as  
20 growth factor releasing factor (GFRF),  $\beta$ MSH, somatostatin, atrial natriuretic  
21 peptide, bradykinin, somatotropin, platelet-derived growth factor,  
22 asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic  
23 gonadotropin, corticotropin (ACTH), epidermal growth factor, erythropoietin,  
24 epoprostenol (platelet aggregation inhibitor), follicle stimulating hormone,  
25 glucagon, hirulog, and other analogs of hirudin, hyaluronidase, interferon,  
26 insulin-like growth factors, interleukin-1, interleukin-2, menotropins  
27 (urofollitropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen  
28 activator, urokinase, vasopressin, desmopressin, ACTH analogs, ANP, ANP  
29 clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists,  
30 antidiuretic hormone antagonists, bradykinin antagonists, CD4, ceredase,  
31 CSF's, enkephalins, FAB fragments, IgE peptide suppressors, IGF-1,

1 neuropeptide Y, neurotrophic factors, oligodeoxynucleotides and their  
2 analogues such as antisense RNA, antisense DNA and anti-gene nucleic  
3 acids, opiate peptides, colony stimulating factors, parathyroid hormone and  
4 agonists, parathyroid hormone antagonists, prostaglandin antagonists,  
5 pentigetide, protein C, protein S, ramoplanin, renin inhibitors, thymosin alpha-  
6 1, thrombolytics, TNF, vaccines, vasopressin antagonist analogs, alpha-1  
7 anti-trypsin (recombinant), and TGF-beta. With electrotransport delivery  
8 devices, it has been recognized that the agents should generally be soluble in  
9 water. It is generally believed that the pathways for electrotransport drug  
10 delivery are hydrophilic pathways or pores such as those associated with hair  
11 follicles and sweat glands. The preferred form of an agent for electrotransport  
12 delivery is hydrophilic (e.g., water soluble salt form).

13           The term "transdermal delivery" refers to the delivery through a  
14 body surface (e.g., skin) of one or more pharmaceutically active agents to be  
15 available for either a local or systemic pharmacological effect. Penetration  
16 enhancers can be used to facilitate absorption through the skin. Such  
17 penetration enhancers include solvents such as water, alcohols including  
18 methanol, ethanol, 2-propanol, dodecanol, dodecanediol and the like, alkyl  
19 methyl sulfoxides, pyrrolidones, laurocapram, acetone, dimethylacetamide,  
20 dimethyl formamide, tetrahydrofurfuryl; surfactants including fatty acids/salts  
21 such as laurates; and chemicals such as urea, N,N-diethyl-m-toluamide, and  
22 the like.

23           The terms "electrotransport", "iontophoresis", and  
24 "iontophoretic" are used herein to refer to the delivery through a body surface  
25 (e.g., skin) of one or more pharmaceutically active agents by means of an  
26 applied electromotive force to an agent-containing reservoir. The agent may  
27 be delivered by electromigration, electroporation, electroosmosis or any  
28 combination thereof. Electroosmosis has also been referred to as  
29 electrohydrokinesis, electro-convection, and electrically induced osmosis. In  
30 general, electroosmosis of a species into a tissue results from the migration of  
31 solvent in which the species is contained, as a result of the application of

1 electromotive force to the therapeutic species reservoir, i.e., solvent flow  
2 induced by electromigration of other ionic species. During the  
3 electrotransport process, certain modifications or alterations of the skin may  
4 occur such as the formation of transiently existing pores in the skin, also  
5 referred to as "electroporation". Any electrically assisted transport of species  
6 enhanced by modifications or alterations to the body surface (e.g., formation  
7 of pores in the skin) are also included in the term "electrotransport" as used  
8 herein. Thus, as used herein, the terms "electrotransport", "iontophoresis"  
9 and "iontophoretic" refer to (1) the delivery of charged agents by  
10 electromigration, (2) the delivery of uncharged agents by the process of  
11 electroosmosis, (3) the delivery of charged or uncharged agents by  
12 electroporation, (4) the delivery of charged agents by the combined  
13 processes of electromigration and electroosmosis, and/or (5) the delivery of a  
14 mixture of charged and uncharged agents by the combined processes of  
15 electromigration and electroosmosis.

16 Transdermal electrotransport flux can be assessed using a  
17 number of in vivo or in vitro methods, well known in the art. In vitro methods  
18 include clamping a piece of skin of an appropriate animal (e.g., human  
19 cadaver skin) between the donor and receptor compartments of an  
20 electrotransport flux cell, with the stratum corneum side of the skin piece  
21 facing the donor compartment. A liquid solution or gel containing the drug to  
22 be delivered is placed in contact with the stratum corneum, and electric  
23 current is applied to electrodes, one electrode in each compartment. The  
24 transdermal flux is calculated by sampling the amount of drug in the receptor  
25 compartment. Two successful models used to optimize transdermal  
26 electrotransport drug delivery are the isolated pig skin flap model of Riviere,  
27 Heit et al, J. Pharm. Sci. (1993) 82:240-243, and the use of isolated hairless  
28 skin from hairless rodents or guinea pigs. See, Hadzija et al., J. Pharm.  
29 Pharmacol. (1992) 44:387-390. See, also, Ogiso et al., Biol. Pharm. Bull.  
30 (1996) 19:1049-1054, for a description of a method for evaluating  
31 percutaneous absorption of insulin.

## II. Modes of Carrying Out the Invention

The present invention concerns the use of dipeptides to buffer transdermal electrotransport reservoir formulations, particularly drug-containing donor reservoir formulations and more particularly donor reservoir formulations used for electrotransport delivery of a polypeptide or protein drug. The method therefore permits increased efficiency of the transdermal delivery of a large number of substances, and allows for the transdermal delivery of molecules that would not otherwise be amenable to such delivery.

In performing electrotransport experiments in animals, it has surprisingly been discovered that some buffers are better suited for pH control. In particular, dipeptide buffers such as Gly-His and His-Glu at their pI are capable of assuring pH control of electrotransport formulations for several hours. Dipeptide buffers for use in the present invention include dipeptides, tripeptides, tetrapeptides, and pentapeptides which contain His, such as His-Gly, Gly-His, Ala-His, L-carnosine (also known as L-Ala-His), His-Ser, His-Ala, Gly-Gly-His (pI = 7.5), His-Gly-Gly (pI = 6.9), Gly-Gly-Gly-His (pI = 7.5), His-Gly-Gly-Gly (pI = 6.9), Gly-Gly-Gly-Gly-His (pI = 7.55), and His-Gly-Gly-Gly-Gly (pI = 6.0).

The dipeptide should have at least two pKa's separated by no more than about 3.5 pH units. Beyond this range, pH control will be poor and conductivity of the solution will be minimal. The pI range of the dipeptide should be between 3 and 10 and the pH of the formulation should be no more than about 1 pH unit away from the isoelectric pH (i.e., the pI) of the dipeptide. Generally, the formulation pH will be from about pH 3 to about pH 9.5. However, the preferred formulation pH will depend on the particular drug and dipeptide buffer used in the formulation. Beyond these pH limits (i.e., less than pH 3 and greater than pH 10), the formulation is likely to be irritating or will result in unacceptable skin resistance. In addition, if the formulation pH is more than 1 pH unit away from the pI of the dipeptide buffer, the effects described above will be inefficient as the dipeptide will start behaving like a conventional buffer (high transport efficiency of charged species and pH

1 drifting). When the dipeptide is used in a solution having a pH at or close to  
2 the pI of the dipeptide (i.e.,  $pI \pm 1.0$  pH unit), minimum competition with the  
3 drug ions (i.e., for electrotransport into the patient) will occur because the  
4 buffer is at or close to electrical (i.e., ionic) neutrality and therefore it can be  
5 used with good results (i.e., little or no ionic competition with the drug ions) in  
6 either the anode or the cathode reservoir formulations. If for technical  
7 reasons it is decided to use the dipeptide at a pH between 0.5 to 1.0 pH unit  
8 away from the pI, the use of the buffer at a pH slightly higher than its pI is  
9 preferred in the cathodic formulation in order to minimize ionic competition  
10 with the drug being delivered. Conversely, and for the same reason, the use  
11 of the dipeptide buffer at a pH slightly below (i.e., between 0.5 to 1.0 pH unit  
12 below) its pI is preferred in the anodic formulation. In the counter reservoir  
13 formulation (i.e., the non-drug containing reservoir) this preference is not as  
14 important as there is no concern over the buffer ions competing with drug ions  
15 for delivery into the patient from the counter reservoir. The dipeptide buffer  
16 will generally be present in the formulation at a concentration of from about 10  
17 mM to 1 M, more preferably from about 10 mM to about 250 mM, and most  
18 preferably from about 25 mM to about 250 mM.

19 Table 1 lists conductivities and solubilities of selected dipeptides  
20 useful in the present invention, at their pI.

0949037 43905160

TABLE 1

Dipeptide	pI	Conductivity at 10 <sup>-2</sup> Molar ( $\mu$ S*/cm)	Solubility (Moles/l)
His-Glu	5.20	40	0.40
His-Asp	5.22	28	0.05
Glu-Lys	6.00	6	1.00
Lys-Glu	6.06	8	0.50
Lys-Asp	6.08	6	1.00
His-Gly	6.90	40	1.00
His-Ala	6.95	60	0.50
Val-His	7.38	94	0.20
Gly-His	7.55	52	1.00
*micro Siemens			

The dipeptide buffer preferably includes at least one amino acid selected from His, Asp, Glu, Lys, Tyr, Arg and Cys; more preferably includes at least one amino acid selected from His, Asp, Glu, and Lys; and most preferably includes at least one amino acid selected from His and derivatives thereof (e.g., methyl-His).

This invention can be practiced in many different ways. In its simplest form, the dipeptide provides pH control to the formulation containing no drug contained in the counter electrode (cathode or anode) reservoir of the electrotransport system. The dipeptide may also be incorporated in the donor (i.e., drug-containing) reservoir formulation (cathodic or anodic).

The buffering of the anodic and/or cathodic reservoirs of a transdermal electrotransport drug delivery device is particularly important because these reservoirs must contain a liquid solution of a drug or other electrolyte. The liquid solvent used for the drug/electrolyte solutions is usually water due to water's excellent biocompatibility. During operation of an electrotransport device, an oxidation reaction takes place at the interface between the anodic electrode and the solution contained in the anodic reservoir. Similarly, an electrochemical reduction reaction takes place at the

1 interface between the cathodic electrode and the solution in the cathodic  
2 reservoir. When the electrodes are composed of electrochemically non-  
3 reactive materials, such as platinum or stainless steel, the water tends to be  
4 the primary species which is either oxidized or reduced, thereby causing a pH  
5 drop in the anodic reservoir and a pH rise in the cathodic reservoir. See for  
6 example, Phipps, et al., U.S. Patent 4,744,787; Phipps, et al., U.S. Patent  
7 4,747,819; and Petelenz, et al., U.S. Patent 4,752,285, the disclosures of  
8 which are incorporated herein by reference. Although the use of  
9 electrochemically reactive electrode materials, such as a silver anode and/or  
10 a silver chloride cathode substantially reduces the oxidation and reduction of  
11 water in electrotransport reservoirs as taught in the above-identified Phipps,  
12 et al. and Petelenz, et al. patents, there is still some tendency for the water in  
13 these reservoirs to be oxidized or reduced during operation of the device,  
14 leading to undesirable pH changes. Thus, while the dipeptide buffers of the  
15 present invention have particular utility in those electrotransport devices  
16 utilizing electrodes composed of materials which are electrochemically non-  
17 reactive, the buffers of the present invention can still find utility even in those  
18 electrotransport devices utilizing electrodes composed of electrochemically  
19 reactive materials.

20 Many dipeptides present adequate characteristics for use in  
21 electrotransport formulation. Table 2 includes a non-exhaustive list of the  
22 dipeptide buffers ranked by increasing pI. Dipeptides having up to five amino  
23 acids and containing the amino acids histidine, lysine, aspartic acid or  
24 glutamic acid in combination or with other amino acids are particularly useful  
25 to this invention.

26

00190887 1133  
00000000 00000000

TABLE 2

Dipeptide	pka A	pka A	pka A	pka B	pka B	pka B	pl	% salt
Asp-Asp	2.70	3.40	4.70	8.26			3.05	43
Gly-Asp	2.81	4.45		8.60			3.60	23
Asp-His	2.45	3.02		6.81	7.98		4.90	3
Glu-His	2.45	3.45		6.81	8.20		5.20	5
His-Glu	2.30	4.19		6.32	8.07		5.20	15
His-Asp	2.28	3.99		6.45	8.19		5.22	11
Glu-Arg	2.66	4.01		7.94	12.50		6.00	2
Glu-Lys	2.85	4.01		7.94	11.07		6.00	2
Arg-Glu	2.74	4.18		7.92	12.50		6.06	3
Lys-Glu	2.74	4.18		7.92	11.12		6.06	3
Arg-Asp	2.64	4.10		8.05	12.50		6.08	2
Lys-Asp	2.64	4.10		8.05	11.20		6.08	2
His-Gly	2.41			5.90	7.91		6.90	16
His-Ala	2.48			6.10	7.80		6.95	22
His-Asn	2.62			6.10	7.80		6.95	22
His-Citrulline	3.05			6.10	7.80		6.95	22
His-Gln	2.93			6.10	7.80		6.95	22
His-Hydroxyproline	2.42			6.10	7.80		6.95	22
His-Isoleucine	3.13			6.10	7.80		6.95	22
His-Leu	3.10			6.10	7.80		6.95	22
His-Met	2.89			6.10	7.80		6.95	22
His-Phe	2.88			6.10	7.80		6.95	22
His-Pro	2.62			6.10	7.80		6.95	22
His-Ser	2.65			6.10	7.80		6.95	22
His-Thr	2.98			6.10	7.80		6.95	22
His-Trp	3.07			6.10	7.80		6.95	22

ACCEPTED

His-Tyr	2.13	9.97		6.10	7.80		6.95	22
His-Val	3.18			6.10	7.80		6.95	22
Asn-His	2.42			6.71	7.30		7.00	44
Thr-His	2.42			6.71	7.60		7.15	39
Tyr-His	2.42	9.90		6.71	7.60		7.15	39
Gln-His	2.42			6.71	7.70		7.20	36
Phe-His	2.42			6.71	7.70		7.20	36
Ser-His	2.42			6.71	7.70		7.20	36
Citrulline-His	2.42			6.71	7.90		7.30	32
Trp-His	2.42			6.71	7.90		7.30	32
Met-His	2.42			6.71	7.97		7.35	30
Val-His	3.09			6.83	7.94		7.38	34
His-His	2.25			5.40	6.80	7.95	7.40	32
Isoleucine-His	2.42			6.71	8.20		7.44	25
Hydroxyproline-His	2.42			6.71	8.23		7.45	25
Leu-His	2.42			6.71	8.25		7.50	24
Ala-His	2.42			6.71	8.37		7.55	22
Gly-His	2.42			6.71	8.39		7.55	22
Beta-Alanylhistidine	2.60			6.70	8.70		7.70	16
Pro-His	2.42			6.71	9.10		7.90	11
Carnosine	2.64			6.83	9.51		8.17	8
Anserine	2.64			7.04	9.49		8.27	10
Tyr-Arg	2.64	9.36		7.39	11.62		8.40	17
Hydroxylysine-His	2.42			6.71	7.40	9.70	8.60	13
His-Hydroxylysine	3.05			6.10	7.80	9.70	8.75	17
Ornithine-His	2.42			6.71	7.30	11.00	9.20	3

SECRET 4306160

His-Lys	3.05			6.10	7.80	11.00	9.40	5
His-Ornithine	2.82			6.10	7.80	11.00	9.40	5
Lys-His	2.42			6.71	8.00	11.00	9.50	5

pKa A = acidic pKa

pKa B = basic pKa

% salt = fraction of the dipeptide that is ionized and carries a net positive and/or negative charge, but not including the ionized species carrying a net neutral charge, in an aqueous solution having a pH equal to the pI

The pH buffering capacity of the dipeptide buffers of the present invention can be explained by using Gly-His at pH 7.5 as an example (the pI of Gly-His is 7.55). At this pH, the net charge of the molecule is essentially zero (see Figure 1). At the pI, three species coexist. The bulk of the molecule (70%) consists of the neutral species which bears two internal charges, one positive and one negative resulting in a net charge of zero. The remaining (30%) consists of the salt form of the positively charged species (1-2+, net charge = +1) and the negatively charged species (-1); see Figure 2). The existence of this salt can be demonstrated by measuring the conductivity of the solution of a Gly-His solution at its pI (Table 1). Although there are small percentages of species presenting a net positive or negative charge in solution, there is minimal ionic transport of these charged species due to charge equilibrium between the three species (i.e., a positive charge migrating in the electric field will revert almost instantly to its neutral form and lose momentum or to its negative form and migrate backward). Due to the same principle of charge equilibrium, any depletion of the charged molecules will be compensated immediately by dissociation of the neutral form to its charged species thereby providing a reservoir insuring long term pH stability. In addition, if loss of the molecule occurs by electroosmosis of the neutral species, this will not result in any pH changes.

The pH buffering capacity of dipeptides at or near their isoelectric pH contrasts sharply with the lack of pH stability observed with

00100897 14393

1 conventional buffers such as phosphate or 3-[N-morpholino] propane sulfonic  
2 acid (MOPS) at the same or higher ionic strength as shown in Table 3. The  
3 decrease of pH observed in the presence of phosphate (a triacid: pKa's of  
4 2.12, 7.2 and 12.32) and MOPS (a zwitterion: pKa's of <1 and 7.2) can be  
5 explained by the fact that these buffers are used at a pH close to their pKa.  
6 The net charge of phosphoric acid and MOPS at pH 7 is respectively -1/5 and  
7 -0.5 (see Figure 3). For phosphoric acid, half of the molecules have a -2  
8 valence and the other half have a -1 valence (see Figure 4). For MOPS, half  
9 of the molecules have a -1 valence and the other half are the neutral form of  
10 the molecule which bears two internal charges, one positive and one negative  
11 (see Figure 5). In an electric field these negative species move in the  
12 opposite direction of their positive associated counterions. This migration will  
13 result in depletion of the charged species and accumulation of the neutral  
14 species in the reservoir resulting in a pH drop. At its pI, MOPS (pI = 4) does  
15 not present any buffering capacity and MOPS solutions at this pH are non-  
16 conductive.

17           Figures 6 and 7 present examples of the charge distribution for  
18 two dipeptides (Glu-His and His-Glu) both having a pI of 5.2. At the pI, the  
19 species presenting a net charge (which assure electrical conductivity)  
20 represent respectively about 5% and 15% of the molecules. Choice of the  
21 dipeptide buffer will be on a case-by-case basis depending on the drug  
22 compound and the desired level of pH control and conductivity of the  
23 formulation. For example with a non-peptidic drug such as fentanyl,  
24 conductivity of the buffer and tight pH control is not essential because the  
25 drug itself is present at high concentration which provides adequate  
26 conductivity and because the charge of the drug is constant in the pH range  
27 zero to seven. For this drug, the buffer Glu-His is a perfect choice. The pI of  
28 this buffer is 5.2 (this pH assures solubility of the drug) and the conductivity of  
29 the buffer is minimal. If more pH control and more conductivity is required, as  
30 with most polypeptide and protein drugs such as goserelin, the buffer His-Glu  
31 is a judicious choice. The pI of this buffer is 5.2 (this pH assures that the

09150887 44299

1 goserelin has optimal charge) and about 15% of the buffer is charged at its pl  
2 assuring good conductivity of the formulation.

3           When used to buffer electrotransport donor (i.e., drug-  
4 containing) reservoir formulations, the present invention is useful for any  
5 number of categories of therapeutic agents (i.e., drugs) and the invention is  
6 not limited thereby. The invention has particular utility in buffering aqueous  
7 polypeptide and protein drug formulations because these drugs are typically  
8 present at low concentration in the donor reservoir formulation, the  
9 detrimental effects caused by competing ions, i.e., decreasing conductivity of  
10 the formulation, decreasing transdermal drug flux, formulation pH drifting, and  
11 local skin irritation, are likely to be more severe. Such protein and  
12 polypeptide drugs include those derived from eucaryotic, procaryotic and viral  
13 sources, as well as synthetic polypeptide drugs. Such polypeptide drugs  
14 include without limitation, polypeptide drugs which are antibiotics and antiviral  
15 agents, antineoplastics, immunomodulators, polypeptide hormones such as  
16 insulin, proinsulin, growth hormone, GHRH, LHRH, EGF, Somatostatin, SNX-  
17 111, BNP, insulinotropin, ANP, and glycoprotein hormones such as, FSH, LH,  
18 PTH and hCG.

19           Examples of protein drugs for use with the present methods  
20 include any commercially available insulins, such as, for example,  
21 recombinant human insulin from Sigma, St. Louis, MO, formulated as neutral  
22 solutions or suspensions of zinc insulin. Such preparations of insulin contain  
23 a minimum of two zinc ions bound per hexamer and have an insulin  
24 concentration from about 0.2 to about 3.0 mM ( $1 \text{ mg mL}^{-1}$  to  $18 \text{ mg mL}^{-1}$ ).  
25 However, insulin preparations including higher concentrations of insulin, up to  
26 about 17 mM insulin will also find use herein.

27           The drug and dipeptide buffer are present in an aqueous  
28 solution since water is by far the most preferred liquid solvent for transdermal  
29 electrotransport drug delivery due to its excellent biocompatibility. In  
30 addition to water, other pharmaceutically acceptable excipients such as  
31 dextrose, glycerol, ethanol, and the like may also be present. If desired, the

1 pharmaceutical composition to be administered may also contain minor  
2 amounts of nontoxic auxiliary substances such as wetting or emulsifying  
3 agents, preservatives, ion-binding agents and the like, for example, sodium  
4 acetate, sorbitan monolaurate, triethanolamine sodium acetate,  
5 triethanolamine oleate, etc. The choice of an appropriate excipient and  
6 additives is determined largely by the drug being delivered. For a discussion  
7 of drug formulations, see, e.g., Remington: The Science and Practice of  
8 Pharmacy, Mack Publishing Company, Easton, Pennsylvania, 19th edition,  
9 1995. For protein drug formulations, such excipients include, without  
10 limitation, preservatives such as methylparaben and phenol (m-cresol);  
11 isotonic agents such as glycerol or salts, including but not limited to NaCl  
12 (generally at a concentration of about 1 to about 100 mM NaCl); and the like.  
13 For a discussion of insulin formulations, see, e.g., Brange, J., Stability of  
14 Insulin (Kluwer Academic Publishers); Brange, J. Galenics of Insulin, The  
15 Physico-chemical and Pharmaceutical Aspects of Insulin and Insulin  
16 Preparations (Springer-Verlag); and Remington: The Science and Practice of  
17 Pharmacy, Mack Publishing Company, Easton, Pennsylvania, 19th edition,  
18 1995.

19           Once the desired drug formulation with the dipeptide buffer is  
20 prepared, it can be used with any of several transdermal electrotransport drug  
21 delivery systems and use is not limited to any one particular electrotransport  
22 system. Examples of electrotransport drug delivery systems are described in,  
23 e.g., U.S. Patents 5,312,326 to Myers et al., 5,080,646 to Theeuwes et al.,  
24 5,387,189 to Gyory et al., and 5,169,383 to Gyory et al., the disclosures of  
25 which are incorporated by reference herein.

26           Figure 8 illustrates a representative electrotransport delivery  
27 device that may be used in conjunction with the present method. Device 10  
28 comprises an upper housing 16, a circuit board assembly 18, a lower housing  
29 20, anode electrode 22, cathode electrode 24, anode reservoir 26, cathode  
30 reservoir 28 and skin-compatible adhesive 30. When the drug to be delivered  
31 is cationic, anodic reservoir 26 will be the donor reservoir and cathodic

1 reservoir 28 will be the counter reservoir. Conversely, when the drug to be  
2 delivered is anionic, cathodic reservoir 28 will be the donor reservoir and  
3 anodic reservoir 26 will be the counter reservoir.

4 Upper housing 16 has lateral wings 15 which assist in holding  
5 device 10 on a patient's skin. Upper housing 16 is preferably composed of an  
6 injection moldable elastomer (e.g., ethylene vinyl acetate). Printed circuit  
7 board assembly 18 comprises an integrated circuit 19 coupled to discrete  
8 components 40 and battery 32. Circuit board assembly 18 is attached to  
9 housing 16 by posts (not shown in Figure 2) passing through openings 13a  
10 and 13b, the ends of the posts being heated/melted in order to heat stake the  
11 circuit board assembly 18 to the housing 16. Lower housing 20 is attached to  
12 the upper housing 16 by means of adhesive 30, the upper surface 34 of  
13 adhesive 30 being adhered to both lower housing 20 and upper housing 16  
14 including the bottom surfaces of wings 15.

15 Shown (partially) on the underside of circuit board assembly 18  
16 is a button cell battery 32. Other types of batteries may also be employed to  
17 power device 10.

18 The device 10 is generally comprised of battery 32, electronic  
19 circuitry 19,40, electrodes 22,24, and drug/chemical reservoirs 26,28, all of  
20 which are integrated into a self-contained unit. The outputs (not shown in  
21 Figure 2) of the circuit board assembly 18 make electrical contact with the  
22 electrodes 24 and 22 through openings 23,23' in the depressions 25,25'  
23 formed in lower housing 20, by means of electrically conductive adhesive  
24 strips 42,42'. Electrodes 22 and 24, in turn, are in direct mechanical and  
25 electrical contact with the top sides 44',44 of drug reservoirs 26 and 28. The  
26 bottom sides 46',46 of drug reservoirs 26,28 contact the patient's skin through  
27 the openings 29',29 in adhesive 30.

28 Device 10 optionally has a feature which allows the patient to  
29 self-administer a dose of drug by electrotransport. Upon depression of push  
30 button switch 12, the electronic circuitry on circuit board assembly 18 delivers  
31 a predetermined DC current to the electrodes/reservoirs 22,26 and 24,28 for

1 a delivery interval of predetermined length. The push button switch 12 is  
2 conveniently located on the top side of device 10 and is easily actuated  
3 through clothing. A double press of the push button switch 12 within a short  
4 time period, e.g., three seconds, is preferably used to activate the device for  
5 delivery of drug, thereby minimizing the likelihood of inadvertent actuation of  
6 the device 10. Preferably, the device transmits to the user a visual and/or  
7 audible confirmation of the onset of the drug delivery interval by means of  
8 LED 14 becoming lit and/or an audible sound signal from, e.g., a "beeper".  
9 Drug is delivered through the patient's skin by electrotransport, e.g., on the  
10 arm, over the predetermined delivery interval.

11 Anodic electrode 22 is preferably comprised of silver and  
12 cathodic electrode 24 is preferably comprised of silver chloride. Both  
13 reservoirs 26 and 28 are preferably comprised of polymer hydrogel materials.  
14 Electrodes 22,24 and reservoirs 26,28 are retained within the depressions  
15 25',25 in lower housing 20.

16 The push button switch 12, the electronic circuitry on circuit  
17 board assembly 18 and the battery 32 are adhesively "sealed" between upper  
18 housing 16 and lower housing 20. Upper housing 16 is preferably composed  
19 of rubber or other elastomeric material. Lower housing 20 is preferably  
20 composed of a plastic or elastomeric sheet material (e.g., polyethylene) which  
21 can be easily molded to form depressions 25,25' and cut to form openings  
22 23,23'. The assembled device 10 is preferably water resistant (i.e., splash  
23 proof) and is most preferably waterproof. The system has a low profile that  
24 easily conforms to the body, thereby allowing freedom of movement at, and  
25 around, the wearing site. The reservoirs 26 and 28 are located on the skin-  
26 contacting side of the device 10 and are sufficiently separated to prevent  
27 accidental electrical shorting during normal handling and use.

28 The device 10 adheres to the patient's body surface (e.g., skin)  
29 by means of a peripheral adhesive 30 which has upper side 34 and body-  
30 contacting side 36. The adhesive side 36 has adhesive properties which  
31 assures that the device 10 remains in place on the body during normal user

1 activity, and yet permits reasonable removal after the predetermined (e.g., 24-  
2 hour) wear period. Upper adhesive side 34 adheres to lower housing 20 and  
3 retains lower housing 20 attached to upper housing 16.

4 The reservoirs 26 and 28 generally comprise a gel matrix, with  
5 the drug solution uniformly dispersed in at least one of the reservoirs 26 and  
6 28. Drug concentrations in the range of approximately  $1 \times 10^{-4}$  M to 1.0 M or  
7 more can be used, with drug concentrations in the lower portion of the range  
8 being preferred. Suitable polymers for the gel matrix may comprise  
9 essentially any nonionic synthetic and/or naturally occurring polymeric  
10 materials. A polar nature is preferred when the active agent is polar and/or  
11 capable of ionization, so as to enhance agent solubility. Optionally, the gel  
12 matrix will be water swellable. Examples of suitable synthetic polymers  
13 include, but are not limited to, poly(acrylamide), poly(2-hydroxyethyl acrylate),  
14 poly(2-hydroxypropyl acrylate), poly(N-vinyl-2-pyrrolidone), poly(n-methylol  
15 acrylamide), poly(diacetone acrylamide), poly(2-hydroxyethyl methacrylate),  
16 poly(vinyl alcohol) and poly(allyl alcohol). Hydroxyl functional condensation  
17 polymers (i.e., polyesters, polycarbonates, polyurethanes) are also examples  
18 of suitable polar synthetic polymers. Polar naturally occurring polymers (or  
19 derivatives thereof) suitable for use as the gel matrix are exemplified by  
20 cellulose ethers, methyl cellulose ethers, cellulose and hydroxylated cellulose,  
21 methyl cellulose and hydroxylated methyl cellulose, gums such as guar,  
22 locust, karaya, xanthan, gelatin, and derivatives thereof. Ionic polymers can  
23 also be used for the matrix provided that the available counterions are either  
24 drug ions or other ions that are oppositely charged relative to the active  
25 agent.

26 Thus, the drug/dipeptide formulations of the present invention  
27 will be incorporated into the drug reservoir, e.g., a gel matrix as just  
28 described, and administered to a patient using an electrotransport drug  
29 delivery system, as exemplified hereinabove. Incorporation of the drug  
30 solution can be done any number of ways, i.e., by imbibing the solution into

1 the reservoir matrix, by admixing the drug solution with the matrix material  
2 prior to hydrogel formation, or the like.

3            Optionally, the outermost layer of the skin may be punctured  
4 with a microblade array before electrotransport delivery therethrough. The  
5 mechanical cutting/puncturing of the stratum corneum is beneficial when  
6 transdermally delivering high molecular weight drugs such as peptides and  
7 proteins. Examples of Microblade arrays, for either skin pretreatment or as  
8 an on board feature of a transdermal electrotransport drug delivery device,  
9 are disclosed in Lee et al. U.S. Patent 5,250,023; Cormier et al. WO  
10 97/48440; and Theeuwes et al. WO 98/28037, the disclosures of which are  
11 incorporated herein by reference.

12            While the invention has been described in conjunction with the  
13 preferred specific embodiments thereof, it is to be understood that the  
14 foregoing description as well as the examples which follow are intended to  
15 illustrate and not limit the scope of the invention. Other aspects, advantages  
16 and modifications within the scope of the invention will be apparent to those  
17 skilled in the art to which the invention pertains.

### 18            **Example 1**

19            A sufficient quantity of His-Gly from BACHEM Bioscience was  
20 added to distilled water to make a 12.5 mM buffer solution having a pH of  
21 6.75. A human growth hormone (hGH) formulation obtained from BresaGen  
22 contained growth hormone, mannitol and glycine in the following proportions:  
23 1:5:1 (w/w). The original hGH formulation was subjected to purification  
24 (diafiltration against 12.5 mM His-Gly buffer to remove the mannitol and  
25 glycine) and the hGH concentration was adjusted to about 20 mg/ml via  
26 ultrafiltration.  
27

28            Aliquots of 250  $\mu$ l of the resulting hGH stock solution were  
29 placed into Eppendorf tubes, each containing 5 mg (2%) of hydroxyethyl  
30 cellulose (HEC) as a gelling agent and the samples were carefully mixed.  
31 After gelation, the samples were tested for stability at body temperature. The

00190887 11438  
00000000 00000000

1 samples were warmed to 32 °C (ie, skin temperature) and assayed at 0, 1, 2,  
2 3, 4, 5, and 6 hours to determine the percent of hGH remaining intact in the  
3 gel. hGH from the gels was extracted by dissolving the gel in 25 ml of His-Gly  
4 buffer. All hGH samples were analyzed by reverse-phase high performance  
5 liquid chromatography (RP), size-exclusion high performance liquid  
6 chromatography (SEC), and ion-exchange high performance liquid  
7 chromatography (IE) to determine percentage of intact hGH remaining (%LS  
8 in Figure 9). The percent of hGH remaining was calculated by measuring the  
9 concentration of the hGH (as determined using one of three high performance  
10 liquid chromatography methods) and dividing that by the initial hGH  
11 concentration. The results of the His-Gly buffered hGH stability tests are  
12 shown in Figure 9.

13 When analyzed by these methods, no significant loss of protein  
14 through degradation was observed in the hGH gel formulations stored at 32  
15 °C. No extra degradation products were discovered.

16 As a comparison, hGH stability studies were run under identical  
17 conditions to those described above, except histidine buffer was substituted  
18 for His-Gly. The results of the histidine stability tests are shown in Figure 10.  
19 Figure 10 shows that after only 6 hours, approximately 50% of the His  
20 buffered hGH remained intact, whereas about 80% of the hGH remained  
21 intact using the His-Gly buffer. As is clearly shown by comparing Figures 9  
22 and 10, substitution of histidine buffer with His-Gly buffer considerably  
23 improved human growth hormone formulation stability.

## 24 **EXAMPLE 2**

25 In vivo iontophoresis experiments were performed using custom  
26 built electrotransport systems. The anodic compartment comprised a skin-  
27 contacting gel containing the aqueous solution of the buffering agent at the  
28 indicated concentration and 3% of the gelling agent hydroxyethyl cellulose  
29 (HEC). This formulation was separated from the anode electrode by a  
30 Sybron ion exchange membrane. A gel containing 0.15M sodium chloride  
31

1 (which acted as the chloride source) was placed between the anode and the  
2 ionic exchange membrane. Alternatively, the anodic compartment comprised  
3 a skin-contacting gel containing the aqueous solution of the buffering agent at  
4 the indicated concentration and 3% HEC as well as 10% of the chloride  
5 source cholestyramine. The cathode-compartment comprised a skin-  
6 contacting gel containing the aqueous solution of the buffering agent at the  
7 indicated concentration and 3% HEC. This formulation was separated from  
8 the cathode electrode by a Nafion ion exchange membrane. A gel containing  
9 0.15M sodium chloride was placed between the cathode and the ionic  
10 exchange membrane.

11 The systems had a silver foil anode and a silver chloride  
12 cathode. The reservoir gel (i.e., both the anodic and cathodic skin-contacting  
13 gels) sizes were each approximately 350  $\mu$ L and had a skin contacting  
14 surface area of about 2 cm<sup>2</sup>. The electrodes were connected to a DC power  
15 source which supplied a constant level of electric current of 0.1 mA/cm<sup>2</sup>.

16 Experiments were performed in vivo in hairless guinea pigs.  
17 Three animals were used for each condition studied. The electrotransport  
18 systems were applied to and removed from the flank of the animals. The two  
19 reservoirs were generally spaced about 5 cm apart. The application site was  
20 wiped with water prior to system application. pH of the gels was measured  
21 prior to application and after removal of the systems using a HORIBA  
22 compact pH meter (Cardy).

23 Table 3 shows that Gly-His and His-Glu at their pI were capable of  
24 assuring pH control of an anodic electrotransport formulation for several  
25 hours. This contrasts with the lack of stability observed with buffers such as  
26 phosphate or MOPS at the same or higher ionic strength.

27 Table 4 shows that Gly-His and His-Glu at their pI were capable of  
28 assuring pH control of a cathodic electrotransport formulation for at least 5  
29 hours. This contrasts with the lack of stability observed with buffers such as  
30 phosphate or MOPS at the same or higher ionic strength.

Table 5 shows that Gly-His and His-Glu at their pI were capable of assuring pH control of anodic and cathodic electrotransport formulations for up to 24 hours.

**Table 3**

Buffer	Ionic strength (approx.)	Initial pH	Anodic pH after 5 h electrotransport
Phosphate 10 mM	0.015	6.9	3.7 to 5.5
Phosphate 33 mM	0.05	6.9	3.3
Phosphate 100 mM	0.15	6.8	6.5
MOPS 20 mM	0.01	7.0	4.1
Gly-His 30 mM	0.007	7.1	7.0
Gly-His 100 mM	0.02	7.4	7.3
Gly-His 250 mM	0.06	7.4	7.3
His-Glu 100 mM	0.015	5.1	5.2
His-Glu 250 mM	0.037	5.2	5.2

**Table 4**

Buffer	Ionic strength (approx.)	Initial pH	Cathodic pH after 5 h electrotransport
Gly-His 100 mM	0.02	7.6	7.3
Gly-His 250 mM	0.06	7.5	7.4
His-Glu 100 mM	0.015	5.3	5.0
His-Glu 250 mM	0.037	5.3	5.0
Phosphate 10 mM	0.015	6.9	4.2
MOPS 20 mM	0.01	7.0	5.4

Table 5

Buffer	Electrode	Initial pH	pH after 24 h electrotransport
Gly-His 100 mM	Anode	7.3	7.2
Gly-His 250 mM	Anode	7.2	7.2
Gly-His 100 mM	Cathode	7.6	7.3
Gly-His 250 mM	Cathode	6.9	7.0
His-Glu 100 mM	Anode	5.1	5.5
His-Glu 250 mM	Anode	5.2	5.4
His-Glu 100 mM	Cathode	5.3	5.4
His-Glu 250 mM	Cathode	5.3	5.2

### Example 3

The effect of the zwitterionic buffer Gly-His at pH 7.5 (pI) on the transdermal delivery of a synthetic radiolabeled decapeptide (DECAD) in the hairless guinea pig was evaluated. This model polypeptide drug is composed of D-amino acids and is excreted unchanged in urine. At pH 7.5 the net charge of DECAD is about +1.6.

The electrotransport systems used in this study had a silver foil anode and a silver chloride cathode. The anodic and cathodic reservoir gels each had a volume of approximately 350 mL and a skin contacting surface area of about 2 cm<sup>2</sup>. The electrodes were connected to a DC power source which supplied a constant level of electric current of 0.100 mA/cm<sup>2</sup>. The anodic reservoir comprised a skin-contacting gel containing the aqueous solution of the buffering agent and DECAD at the indicated concentrations and 3% hydroxyethyl cellulose (HEC) as well as 10% cholestyramine, a high molecular weight resin in chloride salt form which contributes chloride ions into the donor solution without introducing mobile cations which compete with

1 the DECAD for delivery into the animal. The chloride ions from the  
2 cholestyramine resin are provided to react with any silver ions which are  
3 generated by electrochemical oxidation of the silver foil anode, thereby  
4 removing silver cations (ie, as potentially competing with the DECAD cations)  
5 from the donor solution. The cathodic reservoir contained a 0.15 M aqueous  
6 solution of sodium chloride in an HEC gel.

7 Experiments were performed in vivo in hairless guinea pigs. Three  
8 animals were used for each condition studied. The electrotransport systems  
9 were applied to and removed from the flank of the animals. The two  
10 reservoirs were generally spaced about 5 cm apart. The application site was  
11 wiped with water prior to system application. Flux was estimated over a 5  
12 hour delivery period by analyzing the radioactive content of urine excreted for  
13 48 hours. Donor reservoir gel pH was measured prior to application and after  
14 removal of the systems using a HORIBA compact pH meter (Cardy).

15 At concentrations up to 250 mM, Gly-His did not lower significantly the  
16 flux of the DECAD polypeptide as shown in Figure 11. Table 6 shows that in  
17 all experimental conditions tested, the dipeptide Gly-His was capable of  
18 assuring pH control.

19  
20 **Table 6**

Gly-His conc. (mM)	DECAD conc. (mM)	Wearing time (h)	Initial pH	Final pH
100	0.5	5	7.3	7.2
10	5	5	6.9	7.0
30	5	5	7.1	7.0
100	5	5	7.4	7.3
250	5	5	7.4	7.3
100	5	24	7.4	7.3

**Example 4**

The effect of the zwitterionic buffer Gly-His and His-Glu on pH stability of formulations containing small molecular weight drug-like compounds during electrotransport to hairless guinea pigs was studied. Trimethylammonium bromide (TMAB) was used as the cationic model drug and sodium methanesulfate (SMS) was used as the model anionic drug.

The electrotransport systems used in the study had a silver foil anode and a silver chloride cathode. The anodic and cathodic reservoir gels each had a volume of approximately 350  $\mu\text{L}$  and a skin contacting surface area of about 2  $\text{cm}^2$ . The electrodes were connected to a DC power source which supplied a constant level of electric current of 0.100  $\text{mA}/\text{cm}^2$ . The anodic electrode assembly comprised a skin-contacting gel containing the aqueous solution of His-Glu 66 mM or Gly-His 45 mM and TMAB at 50 mM and 3% HEC. This formulation was separated from the silver anode by a Sybron ion exchange membrane. A gel containing 0.15 M sodium chloride (which acted as a chloride source) was placed between the silver anode and the ion exchange membrane. The cathodic electrode assembly comprised a skin-contacting gel containing the aqueous solution of His-Glu 66 mM or Gly-His 45 mM and SMS 50 mM and 3% HEC. The cathodic gel reservoir was separated from the silver chloride cathode by a Nafion ion exchange membrane. A gel containing 0.15M sodium chloride was placed between the cathode and the ion exchange membrane. The ionic strength of the skin-contacting gels was 60 mM.

Experiments were performed in vivo in hairless guinea pigs. Two animals were used for each condition studied. The electrotransport systems were applied to and removed from the backs of the animals. The two reservoirs were generally spaced about 5 cm apart. The application site was wiped with 70% isopropyl alcohol wipes prior to system application. Donor reservoir gel pH was measured prior to application and after removal of the systems using a HORIBA compact pH meter (Cardy).

1            Table 7 shows that in all experimental conditions tested, the dipeptides  
2 Gly-His and His-Glu provided good pH control.

3  
4            **Table 7**  
5

Drug	Buffer	Electrode	Initial pH	Final pH
TMAB 50 mM	His-Glu 66 mM	Anode	5.1	5.3
SMS 50 mM	His-Glu 66 mM	Cathode	5.2	6.0
TMAB 50 mM	Gly-His 45 mM	Anode	7.4	6.9
SMS 50 mM	Gly-His 45 mM	Cathode	7.5	7.9

6  
7            Although preferred embodiments of the subject invention have  
8 been described in some detail, it is understood that obvious variations can be  
9 made without departing from the spirit and the scope of the invention as  
10 defined by the appended claims.

## 1 Claims:

2 1. A formulation for transdermal electrotransport delivery,  
3 comprising an aqueous solution of a drug or an electrolyte and a dipeptide  
4 buffer, the dipeptide buffer comprising a polypeptide chain of 2 to 5 amino  
5 acids and having an isoelectric pH at which the dipeptide carries no net  
6 charge, the dipeptide having at least 2 pKa's which are separated by no more  
7 than about 3.5 pH units, the solution having a pH which is within about 1.0 pH  
8 unit of the isoelectric pH.

9  
10 2. The formulation of claim 1, wherein the isoelectric pH of the  
11 dipeptide is between about 3 and 10.

12  
13 3. The formulation of claim 1, wherein the dipeptide is present  
14 in the solution at a concentration of at least about 10 mM.

15  
16 4. The formulation of claim 1, wherein the dipeptide includes at  
17 least one amino acid selected from the group consisting of His, Tyr, Arg, Cys,  
18 Lys, Asp and Glu.

19  
20 5. The formulation of claim 1, wherein the dipeptide includes  
21 His.

22  
23 6. The formulation of claim 1, wherein the dipeptide is Gly-His.

24  
25 7. The formulation of claim 1, wherein dipeptide is selected  
26 from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu,  
27 His-Asp, Glu-Arg, Glu-Lys, Arg-Glu,, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-  
28 Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-  
29 Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val,  
30 Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His,  
31 Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-

1 His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg,  
2 Hydroxylysine-His, His-Hydroxytyrosine, Ornithine-His, His-Lys, His-Ornithine  
3 and Lys-His.  
4

5 8. The formulation of claim 1, wherein the drug comprises a  
6 polypeptide or a protein.  
7

8 9. A transdermal electrotransport drug delivery device having a  
9 reservoir containing the formulation of claim 1.  
10

11 10. A transdermal electrotransport drug delivery device having  
12 a drug-containing donor reservoir containing the formulation of claim 1.  
13

14 11. A transdermal electrotransport drug delivery device having a  
15 electrolyte-containing counter reservoir containing the formulation of claim 1.  
16

17 12. A method of buffering an aqueous solution of a drug or an  
18 electrolyte used for transdermal electrotransport delivery, comprising buffering  
19 the solution with a dipeptide comprising a chain of 2 to 5 amino acids and  
20 having an isoelectric pH at which the dipeptide carries no net charge, the  
21 dipeptide having at least 2 pKa's which are separated by no more than about  
22 3.5 pH units, the solution having a pH which is within about 1.0 pH unit of the  
23 isoelectric pH.  
24

25 13. The method of claim 12, wherein the isoelectric pH of the  
26 dipeptide is between about 3 and 10.  
27

28 14. The method of claim 12, wherein the dipeptide is present in  
29 the solution at a concentration of at least about 10 mM.  
30

1                   15. The method of claim 12, wherein the dipeptide contains one  
2 or more of His, Tyr, Arg, Cys, Lys, Asp and Glu.

3  
4                   16. The method of claim 12, wherein the dipeptide contains His.

5  
6                   17. The method of claim 12, wherein the dipeptide is Gly-His.

7  
8                   18. The method of claim 12, wherein dipeptide is selected from  
9 the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp,  
10 Glu-Arg, Glu-Lys, Arg-Glu,, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-  
11 Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-  
12 Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val, Asn-His,  
13 Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His,  
14 Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-  
15 His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg,  
16 Hydroxylysine-His, His-Hydroxytlysine, Ornithine-His, His-Lys, His-Ornithine  
17 and Lys-His.

18  
19                   19. The method of claim 12, wherein the drug comprises a  
20 polypeptide or a protein.

21  
22                   20. The method of claim 12, wherein the solution is contained  
23 in a reservoir of a transdermal electrotransport drug delivery device.

**BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL  
ELECTROTRANSPORT DELIVERY**

**Abstract**

Buffered drug formulations for transdermal electrotransport delivery are disclosed. The formulations utilize a dipeptide as a buffer and allow for more efficient electrotransport delivery of drugs, e.g., polypeptide drugs, via the transdermal route.




FIG. 1




FIG. 2

Figure 1 is a line graph showing the charge of Phosphoric acid (solid line) and MOPS (dashed line) as a function of pH. The y-axis is labeled 'Charge' and ranges from -3 to 1. The x-axis is labeled 'pH' and ranges from 0 to 14. Phosphoric acid starts at a charge of 0 at pH 0 and decreases to approximately -3 at pH 14. MOPS starts at a charge of approximately 0.8 at pH 0, drops to 0 by pH 2, remains at 0 until pH 6, then drops to approximately -1 at pH 8, and remains at -1 until pH 14.

FIG. 3




FIG. 4

1




FIG. 6




FIG. 7

FIG. 8




FIG. 9






FIG. 10





**FIG. 11**

Type a plus sign (+) here → +

OO10/PTO Rev. 12/95	US Department of Commerce Patent and Trademark Office	<b>Attorney Docket Number</b> 2589 CIP 1	
<b>DECLARATION</b>		<b>First Named Inventor</b> CORMIER, et al.	
		<b>COMPLETE IF KNOWN:</b>	
		<b>Application Number</b>	
		<b>Filing Date</b>	
		<b>Group Art Unit</b>	
		<b>Examiner Name</b>	
<input type="checkbox"/> Declaration Submitted with Initial Filing    OR <input type="checkbox"/> Declaration Submitted after Initial Filing			

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**BUFFERED DRUG FORMULATIONS FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY***(Title of the Invention)*

the specification of which

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YYYY) (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Copy Attached?	
				Yes	No
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
		<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## DECLARATION

Page 2

I hereby claim the benefit under Title 35, United States Code § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

US Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
08/969,217		11/12/97	

☐ Additional US or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Firm Name: ALZA Corporation

Payor  
Number: 01-1173  
(if applicable)

Name	Registration Number	Name	Registration Number
Steven F. Stone	20,246	D. Byron Miller	30,661
Paul L. Sabatine	22,539	John A. Dhuey	26,265
Michael J. Rafa	38,740	Christopher P. Rogers	36,334
		Pauline Ann Clarke	29,783

☐ Additional attorney(s) and/or agent(s) named on a supplemental sheet attached hereto.

☒ Please direct all correspondence to:

Name:

D. Byron Miller

Address:

ALZA Corporation

Address:

950 Page Mill Road

City:

Palo Alto

State:

CA

Zip:

94303-0802

Country:

U.S.A.

Telephone:

(650) 496-8150

Fax:

(650) 496-8048

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

Michel J.N. Cormier

☐ A petition has been filed for this unsigned inventor.

Given

Name: Michel

Middle

Initial: J.N.


Family

Name: CORMIER


Suffix:

Inventor's

Signature:



Date:



RESIDENCE

City:

Mountain View

State:

CA

Country:

U.S.A.

Citizenship:

French

POST OFFICE ADDRESS

278 Andsbury Avenue

City:

Mountain View

State:

CA

Zip:

94043

Country:

U.S.A.

Applicant

Authority: U.S.

☒ Additional inventors are being named on supplemental sheet(s) attached hereto.

20080120 150

Type a plus sign (+) here → +

062111 2206150

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet	
Name of Additional Joint Inventor, if any: Sara Lee Sendelbeck			<input type="checkbox"/> A petition has been filed for this unsigned inventor.		
Given Name: Sara		Middle Initial: L.	Family Name: SENDELBECK		Suffix:
Inventor's Signature: <i>Sara L. Sendelbeck</i>			Date: <i>November 6, 1998</i>		
RESIDENCE					
City: Palo Alto		State: CA	Country: U.S.A.		Citizenship: U.S.
POST OFFICE ADDRESS		3505 Laguna Avenue			
City: Palo Alto		State: CA	Zip: 94306-2631	Country: U.S.A.	Applicant Authority: U.S.
Name of Additional Joint Inventor, if any: Anna Muchnik			<input type="checkbox"/> A petition has been filed for this unsigned inventor.		
Given Name: Anna		Middle Initial:	Family Name: MUCHNIK		Suffix:
Inventor's Signature: <i>AMuchnik</i>			Date: <i>November 6, 1998</i>		
RESIDENCE					
City: Belmont		State: CA	Country: U.S.A.		Citizenship: U.S.
POST OFFICE ADDRESS		1542 Winding Way			
City: Belmont		State: CA	Zip: 94002	Country: U.S.A.	Applicant Authority: U.S.
Name of Additional Joint Inventor, if any: Iris Ka Man Leung			<input type="checkbox"/> A petition has been filed for this unsigned inventor.		
Given Name: Iris		Middle Initial: K.	Family Name: LEUNG		Suffix:
Inventor's Signature:			Date:		
RESIDENCE					
City: Chesterfield		State: MO	Country: U.S.A.		Citizenship: British National Overseas
POST OFFICE ADDRESS		14727 Greenleaf Valley Drive			
City: Chesterfield		State: MO	Zip: 63017-5514	Country: U.S.A.	Applicant Authority: U.S.
Name of Additional Joint Inventor, if any:			<input type="checkbox"/> A petition has been filed for this unsigned inventor.		
Given Name:		Middle Initial:	Family Name:		Suffix:
Inventor's Signature:			Date:		
RESIDENCE					
City:		State:	Country:		Citizenship:
POST OFFICE ADDRESS					
City:		State:	Zip:	Country:	Applicant Authority:
<input type="checkbox"/> Additional inventors are being named on supplemental sheet(s) attached hereto.					